Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Companion Diagnostics

Scott Patterson's Biography

Scott Patterson, Executive Director, Amgen Inc

Dr. Patterson is an Executive Director in Medical Sciences at Amgen and has for the past decade been involved in translational research, applying biomarkers for pharmacodynamic assessments and ultimately patient selection. He formed and led the Amgen's successful biomarker program as Molecular Sciences head from 2004-2011 and now heads the Medical Sciences-In Vitro Diagnostic Group, responsible for the transition of biomarkers to IVDs. In addition, he has oversight of Device implementation in Early Development and Operations for Medical Sciences. The IVD group is responsible for the biomarker measurement lifecycle strategy for all Amgen products from enablement of clinical validation of the biomarker (encompassing the identification, implementation and management of diagnostic partnering strategies), registration and ongoing post-market access and quality standardization (e.g., the development of KRAS and then RAS as a predictive biomarkers and companion diagnostic for Vectibix® therapy). He has published extensively in the field of proteomics and biomarkers, holds editorial board positions and is a frequent guest lecturer. He was previously Vice President of Proteomics at the Celera Genomics Group and the Chief Scientific Officer of Farmal Biomedicines, LLC. While at Celera, he established the company's initial foray into identification of cell surface targets for oncology, a number of which have been licensed. Dr. Patterson was at Amgen from 1993–2000 ultimately leading the Department of Biochemistry and Genetics. His academic career, encompassing work on analytical protein chemistry applications and apoptosis, began at The University of Queensland where he received his Ph.D. and B.Sc. and held research positions of increasing responsibility to that of Chief Scientific Officer. In 1991 he joined the faculty of Cold Spring Harbor Laboratory, New York.

Scott Patterson Image

Panel Discussion: Emerging Themes in Companion Diagnostics

Monday, 27 October 2014 at 17:00

Add to Calendar ▼2014-10-27 09:00:002014-10-27 10:00:00Europe/LondonCompanion Diagnostics: Evolution and


  • Nicholas Dracopoli, PhD -- Johnson & Johnson
  • Jonathan Pan, PhD -- GlaxoSmithKline
  • Nicole St. Jean, MBA -- AstraZeneca
  • Matthew Marton, PhD -- Merck

Topics for the Panel Discussion:

  • Current Status of the Companion Diagnostics (CDx) Landscape:  Disease Areas and the Types of Companies Participating
  • Types of Deals in this Space and Commercial Strategies:  Collaboration, Partnership, Picture of Deal Considerations/Risks
  • What is Required for Forging a CDx Partnership:  A How-To Guide For New Entrants From the Experts in the Field
  • Areas of Opportunity:  Therapeutic Areas, Technology Platforms, Classes of Biomarkers

Companion Diagnostics: Evolution and Complexities

Monday, 27 October 2014 at 09:00

Add to Calendar ▼2014-10-27 09:00:002014-10-27 10:00:00Europe/LondonCompanion Diagnostics: Evolution and

The model of a single diagnostic used to select patients eligible for a targeted therapy is becoming increasingly challenging within a tumor type given the advent of both multiple biomarkers to define individual patient populations for single therapies and multiple targeted therapies each with their own companion diagnostic. The complexity is further increased with the development of multiple therapies utilizing the same biomarker, but measured with different diagnostics and different selection (cut-off) criteria. Layered on top of that complexity are the differences in implementation diagnostics in various geographies globally. This talk will present some considerations of these topics, both opportunities and challenges.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion